Close button
Enquiry IconContact Us
Logo
  • Choose License Type

Global Parkinson’s Disease Therapeutic Market, by Drug Class (Levodopa, Dopamine agonists, MAO-B inhibitors, Anticholinergics, and Others), by Route of Administration (Oral, Injectable, Nasal, Transdermal, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 4,697.3 Mn in 2021 and is expected to exhibit a CAGR of 6.3% during the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.

Increasing number of awareness campaigns by non-profit organizations and market players is expected to drive the Parkinson’s disease therapeutic market growth during the forecast period. For instance, in April 2019, ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative drugs for the treatment of central nervous system disorders such as Parkinson’s disease, announced the support of several educational events for the Parkinson's community and their caregivers for the occasion of Parkinson’s awareness month.

Global Parkinson’s Disease Therapeutic Market – Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 virus has spread rapidly and infected millions of people worldwide. In March 2020, the World Health Organization (WHO) announced it as a public health emergency and declared it as a pandemic. Many countries such as the U.S., Germany, France, India, and Japan among others have taken significant steps to combat the COVID-19 epidemic. Parkinson's disease (PD) is the world's second most prevalent neurological illness. Restrictions and problems associated with resource movement have negatively affected patients with Parkinson's disease (PD). Access to PD medication is likely to have been affected negatively by COVID-19 and it resulted in the deterioration of patient’s condition suffering from Parkinson's disease.

COVID-19 reduced the availability of Parkinson's disease treatment in Kenya, Bangladesh, Ghana, and the U.S. Patients with Parkinson's disease suffered from increasing impairment as a result of limited drug access. This has led to increasing clinical PD symptoms in the presence of COVID-19, including motor, non-motor, and neuropsychiatric symptoms. Furthermore, governments' efforts to combat COVID-19 may have reduced the availability of healthcare professionals helping Parkinson's disease patients, which also negatively impacted the Parkinson’s disease therapeutic market.

Browse 32 Market Data Tables and 35 Figures spread through 312 Pages and in-depth TOC on “Global Parkinson’s Disease Therapeutic Market”- Forecast to 2028, Global Parkinson’s Disease Treatment Market, by Drug Class (Levodopa, Dopamine Agonists, MAO-B Inhibitors, Anticholinergics, and Others), by Route of Administration (Oral, Injectable, Nasal, Transdermal and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the Global Parkinson’s Disease Therapeutic Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/parkinsons-disease-therapeutic-market-494

Rising product launches by key market players is expected to boost the Parkinson’s disease therapeutic market growth during the forecast period. For instance, Eisai Co., Ltd. announced launch of Equfina 50mg TABLETS (safinamide mesilate, Equfina) for the indication of improvement of wearing-off phenomenon in patients with Parkinson’s disease under treatment with a drug containing levodopa. Manufacturing and marketing approval of Equfina were obtained on September 20, 2019 and Equfina was included to Japan’s National Health Insurance Drug Price List on November 19, 2019.

Key Takeaways of the Global Parkinson’s Disease Therapeutic Market:

  • The global Parkinson’s disease therapeutic market is expected to exhibit a CAGR of 6.3% during the forecast period, owing to strong focus of key players on inorganic growth strategies such as product launch, acquisition, merger, collaboration etc. to enhance market position, strengthen product portfolio, and to increase the product reach is expected to drive growth of the global market. For instance, in June 2021, Melior Pharmaceuticals signed a ‘letter of intent’ with Adhera Therapeutics, Inc. to acquire MLR-1019 (armesocarb) Parkinson’s disease (PD) candidate.
  • Among drug class, levodopa segment is estimated to account for largest market share in the global Parkinson’s disease therapeutic market in 2021. Levodopa (also known as L-dopa) is the most widely prescribed medication for Parkinson's disease, and it has high potency against the disease. For instance, according to an article published in PLOS ONE a scientific journal, levodopa was the most frequently prescribed first-line medication with 70.1% in the U.S. and 29.0% in the U.K. during the period 2012-2017.
  • Among route of administration, oral segment is estimated to account for largest market share in the global Parkinson’s disease therapeutic market in 2021. Increasing product launches, approvals and research & development activities for the treatment of Parkinson’s disease are some of the major factors that are expected to drive growth of the oral segment. For instance, in August 2019, Kyowa Kirin Co., Ltd., a Japan-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved NOURIANZ (istradefylline) as an add-on treatment to levodopa / carbidopa in adult patients with Parkinson’s disease (PD) experiencing ‘OFF’ episodes. An ‘off’ episode is a time when a patient's medication is not working well, leading to increased symptoms of Parkinson's disease such as tremors and difficulty in walking.
  • Among distribution channel, hospital pharmacies segment is estimated to account for largest market share in the global Parkinson’s disease therapeutic market in 2021. Hospital pharmacies are the primary distribution channel for both generic and branded anti-Parkinson’s disease drugs. Ease of availability of various types of dosage forms at hospital pharmacies and surge in number of patients with Parkinson’s disease (PD) are factors that are expected to drive the growth of the segment. For instance, according to Parkinson’s UK, 98,195 people with Parkinson's disease were admitted to hospitals in 2012-2013 in England.
  • Among regions, North America is estimated to hold dominant position in the global Parkinson’s disease therapeutic market in 2021, owing to the increasing regulatory approvals for PD treatment medicines in the region. For instance, in February 2021, Gocovri (Amantadine), an extended release capsule, received approval from the U.S. Food and Drug Administration (FDA) for patients with Parkinson’s disease. It is approved as an adjunctive treatment to levodopa/carbidopa in patients with PD.
  • Major players operating in the global Parkinson’s disease therapeutic market include Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline Plc., AbbVie Inc., Merck & Co., Inc., Zydus Cadila, Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries Ltd., Cipla Inc., and Boehringer Ingelheim International GmbH
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly subscribe for our latest news & articles.